PASTIC Dspace Repository

HPLC DETERMINATION OF IMATINIB IN PLASMA AND TISSUES AFTER MULTIPLE ORAL DOSE ADMINISTRATION TO MICE

Show simple item record

dc.contributor.author M, TEOH
dc.contributor.author P, NARAYANAN
dc.contributor.author KS, MOO
dc.contributor.author S, RADHAKRISMAN
dc.contributor.author R, PILLAPPAN
dc.contributor.author NI, BUKHARI
dc.contributor.author I, SEGARRA
dc.date.accessioned 2022-11-29T06:12:09Z
dc.date.available 2022-11-29T06:12:09Z
dc.date.issued 2010-01-20
dc.identifier.citation Teoh, M., Narayanan, P., Moo, K. S., Radhakrisman, S., Pillappan, R., Bukhari, N. I., & Segarra, I. (2010). HPLC determination of imatinib in plasma and tissues after multiple oral dose administration to mice. Pak J Pharm Sci, 23(1), 35-41. en_US
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/14207
dc.description.abstract Imatinib inhibits Bcr-Abl, c-KIT and PDGFR kinases. It is approved for the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) and has further therapeutic potential. Male ICR mice were given imatinib PO (50 or 25 mg/kg, 5 doses every 2 h); euthanized 2 h after the last dose administration; plasma, liver, brain, spleen and kidney were collected and imatinib concentration measured by an optimized HPLC method for quantification in tissues. Methanol (1:1 v/v plasma) and pH 4, 40:30:30 (v/v/v) watermethanol-acetonitrile at 5 ml/g (brain) and 10 ml/g (spleen, kidney, liver) ratio was added to the samples, homogenized, sonicated, centrifuged (15,000 rpm, 5 min, 2ºC) and the supernatant injected into an Inertsil® CN-3 column (4.6 mm x 150 mm, 5 µm) using 64:35:1 (v/v/v) water-methanol-triethylamine (pH 4.8), flow rate 1 ml/min, 25ºC. Imatinib eluted at 7.5 min (268 nm). Linearity: 0.1-50 µg/ml; precision, accuracy, inter- and intra-day variability was within 15%. Recovery was above 95% (plasma), 80% (brain) and 90% (kidney, liver, spleen). Imatinib tissue concentrations were 6-8 folds higher than plasma except brain, where the ratio decreased from 0.24 to 0.08 suggesting limited brain penetration, likely due to blood brain barrier efflux transporters. The extensive distribution supports the expansion of therapeutic applications. en_US
dc.language.iso en en_US
dc.publisher Karachi:Pakistan Journal of Pharmaceutical Sciences, university of Karachi. en_US
dc.subject Imatinib en_US
dc.subject tissue distribution en_US
dc.subject brain en_US
dc.subject HPLC. en_US
dc.title HPLC DETERMINATION OF IMATINIB IN PLASMA AND TISSUES AFTER MULTIPLE ORAL DOSE ADMINISTRATION TO MICE en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account